DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Journal for ImmunoTherapy of Cancer (2021) 9:e002226. https://doi.org/10.1136/jitc-2020-002226
- Event
-
Veröffentlichung
- (where)
-
Würzburg
- (who)
-
Universität Würzburg
- (when)
-
2024
- Creator
-
Filipski, Katharina
Scherer, Michael
Zeiner, Kim N.
Bucher, Andreas
Kleemann, Johannes
Jurmeister, Philipp
Hartung, Tabea I.
Meissner, Markus
Plate, Karl H.
Fenton, Tim R.
Walter, Jörn
Tierling, Sascha
Schilling, Bastian
Zeiner, Pia S.
Harter, Patrick Nikolaus
- DOI
-
10.1136/jitc-2020-002226
- URN
-
urn:nbn:de:bvb:20-opus-330118
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Filipski, Katharina
- Scherer, Michael
- Zeiner, Kim N.
- Bucher, Andreas
- Kleemann, Johannes
- Jurmeister, Philipp
- Hartung, Tabea I.
- Meissner, Markus
- Plate, Karl H.
- Fenton, Tim R.
- Walter, Jörn
- Tierling, Sascha
- Schilling, Bastian
- Zeiner, Pia S.
- Harter, Patrick Nikolaus
- Universität Würzburg
Time of origin
- 2024
Other Objects (12)
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial
Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma
E2F1 inhibition mediates cell death of metastatic melanoma
Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial
Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma
E2F1 inhibition mediates cell death of metastatic melanoma
Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial
Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma
E2F1 inhibition mediates cell death of metastatic melanoma
Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma